Understanding and managing cancer cachexia

Journal of the American College of Surgeons

Volumn 197, Issue 1, 2003, Pages 143-161

  MacDonald, Neil ^a   Easson, Alexandra M ^b   Mazurak, Vera C ^c   Dunn, Geoffrey P ^d   Baracos, Vickie E ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HAMOT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; ANABOLIC AGENT; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; CANNABINOID; CHOLECYSTOKININ; CORTICOSTEROID; CREATINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GESTAGEN; INSULIN; LAXATIVE; MACROLIDE; MULTIVITAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OPIATE; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN; STATINE; TESTOSTERONE; THALIDOMIDE; UNINDEXED DRUG; ZINC;

ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; BREAST CANCER; BREAST METASTASIS; CACHEXIA; CANCER; CANCER ADJUVANT THERAPY; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE DISEASE; FOLLOW UP; HUMAN; MALABSORPTION; MOUTH ULCER; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 0038310898     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(03)00382-X     Document Type: Article

References (168)

1. Easson AM, Hinshaw DB, Johnson DL. The role of tube feeding and total parenteral nutrition in advanced illness. J Am Coll Surg 2002; 194:225-228.
2. Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-868.
3. Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care 2002;5:237-239.
4. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 2000;16:1015-1018.
5. Costelli P, Baccino FM. Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care 2000;3:177-181.
6. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999;19:223-248.
7. Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer 2001;92[6 Suppl]:1669-1677.
8. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001;86:5108-5117.
9. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871.
10. Argiles JM, Alvarez B, Carbo N, et al. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur Cytokine Netw 2000;11:552-559.
11. Barber MD, Powell JJ, Lynch SF, et al. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 2000;83:1443-1447.
12. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-634.
13. Wigmore SJ, MacMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001;88:255-260.
14. Fischer CP, Bode BP, Souba WW. A sarcoma-derived protein regulates hepatocyte metabolism via autocrine production of tumor necrosis factor-alpha. Ann Surg 1996;224:476-483.
15. Costelli P, Llovera M, Carbo N, et al. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 1995;95: 33-38.
16. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993;92:2783-2789.
17. Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998;142: 183-189.
18. Fujita J, Tsujinaka T, Yano M, et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996;68:637-643.
19. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care 2002;5:377-383.
20. Ross JA, Fearon KC. Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 2002;5:241-248.
21. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12, 14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003; 103:84-90.
22. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002; 62:6706-6711.
23. Cahlin C, Gelin J, Delbro D, et al. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 2000;60:1742-1749.
24. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002;61:345-358.
25. Tisdale MJ. 'The cancer cachectic factor.' Support Care Cancer 2003;11:73-78.
26. Lorite MJ, Smith HJ, Arnold JA, et al. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001;85:297-302.
27. Mikasa K, Sawaki M, Kita E, et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 1997;43:288-296.
28. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292: 156-163.
29. Sakamoto M, Mikasa K, Majima T, et al. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer. Chemotherapy 2001;47:444-451.
30. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999;10:857-859.
31. Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging 2002;19:85-100.
32. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76:1035-1040.
33. Cariuk P, Lorite MJ, Todorov PT, et al. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997;76:606-613.
34. Lorite MJ, Thompson MG, Drake JL, et al. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998;78:850-856.
35. Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 1999;80:1734-1737.
36. Cabal-Manzano R, Bhargava P, Torres-Duarte A, et al. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001;84:1599-1601.
37. Wigmore SJ, Todorov PT, Barber MD, et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53-58.
38. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999;97:215-223.
39. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001;4:183-190.
40. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
41. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001;280:R1518-R1523.
42. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003;237:384-389.
43. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995;268:E996-1006.
44. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
45. Holmes-McNary M. Nuclear factor kappa B signaling in catabolic disorders. Curr Opin Clin Nutr Metab Care 2002;5: 255-263.
46. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-246.
47. Watchorn TM, Waddell I, Dowidar N, Ross JA. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J 2001;15: 562-564.
48. Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab 1999;84:3515-3521.
49. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, et al. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 2003;88:358-362.
50. Mackenzie M, Baracos VE. Cancer-associated cachexia: altered metabolism of protein and amino acids. In: Cynober L, ed. Amino acid metabolism and therapy in health and diseases. Palm Springs, FL: CRC Press; 2003 (in press).
51. Kaibara A, Yoshida S, Yamasaki K, et al. Effect of glutamine and chemotherapy on protein metabolism in tumor-bearing rats. J Surg Res 1994;57:143-149.
52. Austgen TR, Dudrick PS, Sitren H, et al. The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues. Ann Surg 1992;215:107-113.
53. Yoshida S, Kaibara A, Yamasaki K, et al. Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. JPEN J Parenter Enteral Nutr 1995;19:492-497.
54. Le Bricon T, Cynober L, Field CJ, Baracos VE. Supplemental nutrition with ornithine alpha-ketoglutarate in rats with cancer-associated cachexia: surgical treatment of the tumor improves efficacy of nutritional support. J Nutr 1995;125:2999-3010.
55. Reeds PJ, Fjeld CR, Jahoor F. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 1994;124:906-910.
56. Anthony JC, Yoshizawa F, Anthony TG, et al. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. J Nutr 2000;130:2413-2419.
57. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomized clinical trials. Ann Oncol 2001;12:289-300.
58. Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998;25[2 Suppl 6]:45-52.
59. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99-102.
60. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol 2000;18:2930-2932.
61. Lambert CP, Sullivan DH, Freeling SA, et al. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2002;87:2100-2106.
62. Loprinzi CL, Schaid DJ, Dose AM, et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-154.
63. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996;14:135-141.
64. Macbeth FR, Gregor A, Cottier B. Randomized study of megestrol acetate and prednisolone for anorexia and weight loss in patients with lung cancer. World Conference on Lung Cancer Abstract 334; 1994.
65. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
66. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: a randomized trial and cohort study. JAMA 2001;286:64-70.
67. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
68. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-2082.
69. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003;11:60-62.
70. Boehm M, Nabel EG. Angiotensin-converting enzyme 2 - a new cardiac regulator. N Engl J Med 2002;347:1795-1797.
71. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002;91:988-998.
72. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002;359:926-930.
73. Montgomery H, Clarkson P, Barnard M, et al. Angiotens-inconverting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 1999;353:541-545.
74. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-1078.
75. Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001;358:539-544.
76. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349-353.
77. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995;210:781-786.
78. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996;40:1366-1370.
79. Yanagihara K, Tomono K, Kuroki M, et al. Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa. Clin Exp Immunol 2000;122:67-71.
80. Sassa K, Mizushima Y, Fuji'shita T, et al. Therapeutic effect of clarithromycin on a transplanted tumor in rats. Antimicrob Agents Chemother 1999;43:67-72.
81. Hamada K, Mikasa K, Yunou Y, et al. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 2000;46:49-61.
82. Yatsunami J, Fukuno Y, Nagata M, et al. Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett 1999;147:17-24.
83. Huso ME, Hampl JS, Johnston CS, Swan PD. Creatine supplementation influences substrate utilization at rest. J Appl Physiol 2002;93:2018-2022.
84. Kreider RB, Ferreira M, Wilson M, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. Med Sci Sports Exerc 1998;30:73-82.
85. Volek JS, Duncan ND, Mazzetti SA, et al. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Med Sci Sports Exerc 1999;31:1147-1156.
86. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 1998;8:286-297.
87. Izquierdo M, Ibanez J, Gonzalez-Badillo JJ, Gorostiaga EM. Effects of creatine supplementation on muscle power, endurance, and sprint performance. Med Sci Sports Exerc 2002;34:332-343.
88. Gotshalk LA, Volek JS, Staron RS, et al. Creatine supplementation improves muscular performance in older men. Med Sci Sports Exerc 2002;34:537-543.
89. Agteresch HJ, Rietveld T, Kerkhofs LG, et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002;20:371-378.
90. Juhn MS, Tarnopolsky M. Potential side effects of oral creatine supplementation: a critical review. Clin J Sport Med 1998;8:298-304.
91. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001;17[1 Suppl]:S1-20.
92. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002;282:E601-E607.
93. Spratt DI. Altered gonadal steroidogenesis in critical illness: is treatment with anabolic steroids indicated? Best Pract Res Clin Endocrinol Metab 2001;15:479-494.
94. Von Roenn J, Tchekmedyian S, Ottery FD. Oxandrolone increases weight, lean tissue, performance status and quality of life scores in cancer related weight loss. Support Care Cancer Abstract 2002.
95. Padero MC, Bhasin S, Friedman TC. Androgen supplementation in older women: too much hype, not enough data. J Am Geriatr Soc 2002;50:1131-1140.
96. Taggart DP, Gray CE, Bowman A, et al. Serum androgens and gonadotrophins in bronchial carcinoma. Respir Med 1993;87: 455-460.
97. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition 1996;12[1 Suppl]:S43-S47.
98. Sheffield-Moore M, Urban RJ, Wolf SE, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999;84:2705-2711.
99. Wolfe R, Ferrando A, Sheffield-Moore M, Urban R. Testosterone and muscle protein metabolism. Mayo Clin Proc 2000;75[Suppl]:S55-S59.
100. Amory JK, Chansky HA, Chansky KL, et al. Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc 2002;50:1698-1701.
101. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000;283:763-770.
102. Fairfield WP, Treat M, Rosenthal DI, et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. J Appl Physiol 2001;90:2166-2171.
103. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002;2:692-699.
104. Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 2002;85:151-159.
105. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-3306.
106. Bishop JF, Smith JG, Jeal PN, et al. The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial. Eur J Cancer 1993;29A:814-818.
107. Chlebowski RT, Herrold J, Ali I. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183-186.
108. Hack V, Breitkreutz R, Kinscherf R, et al. The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood 1998;92:59-67.
109. May PE, Barber A, D'Olimpio JT, et al. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg 2002;183:471-479.
110. Jones PJH, Kubow S. Lipids, sterols, and their metabolites. In: Shils ME, Olson JA, Shike M, Ross AC, eds. Modern nutrition in health and disease. Baltimore, MD: Williams & Wilkins; 1998:85.
111. Clandinin JJ, Jumpsen J, Suh M. Relationship between fatty acid accretion, membrane composition, and biologic functions. J Pediatr 1994;125:S25-S32.
112. Calder PC. More good news about fish oil. Nutrition 2001; 17:158-160.
113. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985;312:1217-1224.
114. Barber MD, Ross JA, Preston T, et al. Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr 1999;129:1120-1125.
115. Hardman WE, Moyer MP, Cameron IL. Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT- 11 (irinorecan) in mice. Br J Cancer 2002;86: 983-988.
116. Hardman WE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 1999;81:440-448.
117. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999;5:3942-3947.
118. Wigmore SJ, Barber MD, Ross JA, et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36:177-184.
119. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998; 82:395-402.
120. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003;21:129-134.
121. Pratt VC, Watanabe S, Bruera E, et al. Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer 2002;87: 1370-1378.
122. Barber MD, Fearon KC, Tisdale MJ, et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001;40:118-124.
123. Jatoi A, Rowland KM Jr, Loprinzi CL, et al. A phase III, double blind, placebo-controlled randomized comparison of megestrol acetate (megace) versus an omega-3 fatty acid (EPA)-enriched nutritional supplement versus both. Abstract # American Society of Clinical Oncology, 2003.
124. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994;272:1263-1266.
125. Bruera E, Kuehn N, Miller MJ et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
126. European Organization for Research and Treatment of Cancer (EORTC) quality of life Web page. Available at: www.eortc.be/home/qol. Accessed April 4, 2003.
127. Kaasa T, Wessel J. The Edmonton Functional Assessment Tool: further development and validation for use in palliative care. J Palliat Care 2001;17:5-11.
128. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-573.
129. Erkurt E, Erkisi M, Tunali C. Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. J Exp Clin Cancer Res 2000;19:431-439.
130. Nelson KA, Walsh D, Hussein M. A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in non-hormonally dependent cancer. Am J Hosp Palliat Care 2002; 19:206-210.
131. Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Invest 2001;24:31-36.
132. Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002;121:1070-1078.
133. Yeh SS, Wu SY, Lee TP, et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000;48:485-492.
134. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-238.
135. McIntyre RS, McCann SM, Kennedy SH. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62:41-44.
136. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62 [Suppl 2]:41-44.
137. Jatoi A, Daly BD, Hughes VA, et al. Do patients with non-metastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001;72:348-351.
138. MacIntosh CG, Morley JE, Wishart J, et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001;86:5830-5837.
139. MacIntosh CG, Horowitz M, Verhagen MA, et al. Effect of small intestinal nutrient infusion on appetite, gastrointestinal hormone release, and gastric myoelectrical activity in young and older men. Am J Gastroenterol 2001;96:997-1007.
140. van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blomberg-van der Flier BM, et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr 2001;73:323-332.
141. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr 2000;24:133-139.
142. Hiroshige K, Sonta T, Suda T, et al. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 2001;16:1856-1862.
143. Tipton KD, Rasmussen BB, Miller SL, et al. Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise. Am J Physiol Endocrinol Metab 2001; 281:E197-E206.
144. Carroll PV. Treatment with growth hormone and insulin-like growth factor-I in critical illness. Best Pract Res Clin Endocrinol Metab 2001;15:435-451.
145. Crown AL, Cottle K, Lightman SL, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 2002;56:723-733.
146. Brink M, Anwar A, Delafontaine P. Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol 2002;85:111-121.
147. Esmarck B, Andersen JL, Olsen S, et al. Timing of postexercise protein intake is important for muscle hypertrophy with resistance training in elderly humans. J Physiol 2001;535:301-311.
148. Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care 2002;5:271-279.
149. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-135.
150. Schulze PC, Gielen S, Schuler G, Hambrecht R. Chronic heart failure and skeletal muscle catabolism: effects of exercise training. Int J Cardiol 2002;85:141-149.
151. Barber MD, Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 2001;36:347-351.
152. Barber MD, Ross JA, Fearon KC. Disordered metabolic response with cancer and its management. World J Surg 2000; 24:681-689.
153. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res 2000;60:5289-5295.
154. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002;85:161-171.
155. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 2002;85:173-183.
156. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-130.
157. Mesa JL, Ruiz JR, Gonzalez-Gross MM, et al. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med 2002;32:903-944.
158. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in Doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-4522.
159. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
160. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002;4:765-770.
161. Gould PA, Kaye DM. Clinical treatment regimens for chronic heart failure: a review. Expert Opin Pharmacother 2002;3: 1569-1576.
162. Walsh TD, Rivera NI. Adenosine triphosphate for cancer cachexia. Curr Oncol Rep 2002;4:231-232.
163. Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:321-328.
164. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-2511.
165. Hyltander A, Daneryd P, Sandstrom R, et al. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer 2000;36:330-334.
166. Gambardella A, Tortoriello R, Pesce L, et al. Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients. Metabolism 1999;48:291-297.
167. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3:381-387.
168. Daneryd P. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients. Semin Oncol 2002;29[Suppl 8]:69-74.